[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report
Rhea-AI Filing Summary
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini filed Amendment No. 8 to their Schedule 13D on Royalty Pharma plc, updating their ownership and corporate details. As of June 12, 2026, they may be deemed to beneficially own 21,366,927 Class A shares, representing 4.8% of the outstanding class based on 443,274,104 shares. The amendment notes that they are no longer deemed beneficial owners of more than five percent of Royalty Pharma’s Class A shares and states this is their final amendment and exit filing. The filing also records the trust and fund structure through which the shares are held and disclaims beneficial ownership by various board members and beneficiaries.
Positive
- None.
Negative
- None.
Insights
Major Royalty Pharma holder reports ownership down to 4.8%, exiting 13D status.
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini report beneficial ownership of 21,366,927 Royalty Pharma Class A shares, or 4.8% of the class, through the MGG Strategic and GG Strategic sub-funds and related trusts.
The filing states that, as of June 12, 2026, they are no longer deemed beneficial owners of more than five percent, making this a final, “exit” amendment to their Schedule 13D. Board members, trust beneficiaries, and the trustee all formally disclaim beneficial ownership of the shares.
For investors, this moves the group from large shareholder (above five percent) into a sub‑5% position. Future company filings may clarify any further changes in Royalty Pharma’s shareholder base or additional transactions by these related entities.